Elutia (ELUT) Set to Post Quarterly Earnings on Thursday

Elutia (NASDAQ:ELUT) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.90 million. Elutia had a negative return on equity of 407.37% and a net margin of 426.93%.

Elutia Price Performance

Shares of Elutia stock opened at $0.84 on Thursday. Elutia has a one year low of $0.50 and a one year high of $1.39. The business’s 50 day simple moving average is $0.84 and its two-hundred day simple moving average is $0.97. The stock has a market capitalization of $37.20 million, a P/E ratio of 0.88 and a beta of 0.84.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Elutia from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Elutia has a consensus rating of “Sell”.

About Elutia

Elutia Inc is a medical technology company focused on developing and commercializing biologic products designed to support tissue healing and improve the performance of implantable medical devices. The company combines human tissue-based materials with drug-delivery and regenerative medicine technologies.

Its product portfolio includes biologic envelopes used to protect and support cardiac implantable electronic devices, including pacemakers and defibrillators. Elutia also develops tissue matrices and other biologic products for orthopedic, wound care and related surgical applications, with products intended to support soft-tissue repair, reconstruction and healing.

The company was formerly known as Aziyo Biologics and adopted the Elutia name as part of its broader focus on bioelectronic medicine and regenerative healthcare.